Immunocore Holdings plc - American Depositary Shares (IMCR)
Frequently Asked Questions About Immunocore Holdings plc - American Depositary Shares (IMCR)
Has Immunocore received any regulatory approvals for its therapies?
Yes, Immunocore received accelerated approval from the U.S. Food and Drug Administration (FDA) for Imcivree in February 2022, which marked a significant milestone as it was the first-ever approved therapy utilizing T cell receptor technology for metastatic uveal melanoma. This approval reflects the therapeutic promise of Immunocore's innovative approach.
How does Immunocore approach research and development?
Immunocore adopts a comprehensive approach to research and development by integrating cutting-edge scientific advancements with focused clinical strategies. The company collaborates with academic institutions and industry partners to leverage shared expertise, driving innovation in T cell therapies and achieving rapid progress in clinical development.
How does Immunocore maintain its regulatory compliance?
Immunocore maintains regulatory compliance by adhering to established guidelines set forth by governing bodies such as the FDA and EMA. The company employs a dedicated regulatory affairs team that ensures all clinical trials and product registrations meet regulatory standards, fostering transparency and safety throughout its operations.
How does Immunocore plan to expand its pipeline?
Immunocore plans to expand its pipeline by investing in research to develop new therapies targeting various cancers and autoimmune diseases. The company aims to explore combinations of its T cell receptor technologies with existing treatments to enhance patient outcomes and broaden its therapeutic reach.
Is Immunocore publicly traded, and if so, under what symbol?
Yes, Immunocore is publicly traded on the NASDAQ stock exchange under the ticker symbol IMCR. The company went public in March 2021, providing it with the capital to further its drug development and operational endeavors.
What are some upcoming milestones for Immunocore?
Upcoming milestones for Immunocore include advancing clinical programs for Imcivree in additional indications, expanding its pipeline of T cell receptor therapies, and conducting further studies to assess the efficacy and safety of its drug candidates. The company remains focused on delivering significant scientific advancements in oncology.
What are the major challenges facing Immunocore?
Major challenges facing Immunocore include navigating the competitive landscape of immuno-oncology and ensuring regulatory compliance for its therapies. Additionally, the company must continuously demonstrate the efficacy and safety of its drug candidates in clinical trials to gain and maintain acceptance from the medical community and market.
What does Immunocore Holdings plc do?
Immunocore Holdings plc is a biotechnology company that specializes in the development of innovative therapies for cancer and other serious diseases. The company focuses on employing its proprietary ImmTAC technology to create T cell receptor therapies, enabling the immune system to target and attack intracellular pathogens and tumors, showcasing significant potential in achieving better treatment outcomes.
What impact has COVID-19 had on Immunocore?
The COVID-19 pandemic has impacted many biotechnology companies, including Immunocore, in terms of clinical trial timelines and operational logistics. However, Immunocore has adapted by implementing remote monitoring strategies and prioritizing projects that align with public health needs, showcasing resilience in navigating these unprecedented challenges.
What is Imcivree, and what is its primary indication?
Imcivree (tebentafusp) is Immunocore's lead product candidate, specifically designed for the treatment of metastatic uveal melanoma, an aggressive form of eye cancer. It is the first T cell receptor therapy approved by regulatory authorities, highlighting the advancement of Immunocore's proprietary platform in oncology.
What is Immunocore’s vision for the future?
Immunocore’s vision for the future is to become a leader in the field of immune-oncology by advancing innovative therapies that harness the power of the immune system. The company strives to develop safe and effective treatments that provide hope for patients with serious diseases, ultimately transforming cancer care.
What is the corporate governance structure of Immunocore?
Immunocore maintains a board of directors comprising experienced leaders from the biotech and pharmaceutical industries, ensuring that the company adheres to best practices in corporate governance. The board is responsible for overseeing company strategy, risk management, and compliance with financial and regulatory obligations.
What is the primary technology behind Immunocore's therapies?
The primary technology behind Immunocore's therapies is ImmTAC, which stands for Immune mobilizing monoclonal TCRs against cancer. This unique platform leverages engineered T cell receptors that can recognize and bind to specific peptide-major histocompatibility complex (pMHC) targets on cancer cells, facilitating the targeted activation of T cells to eliminate the tumor.
What is the significance of Immunocore's ImmTAC technology?
The significance of Immunocore's ImmTAC technology lies in its ability to robustly redirect T cells to efficiently target and kill cancer cells, providing a new avenue for treatment in oncology. This technology enhances the precision of therapies by identifying specific antigens presented on tumor cells while sparing healthy cells.
What partnerships or collaborations does Immunocore have?
Immunocore actively seeks partnerships and collaborations with various pharmaceutical companies and research institutions. These alliances are aimed at synergizing efforts in drug development, sharing expertise, and leveraging resources to accelerate the clinical advancement of its T cell receptor therapies.
What specific diseases does Immunocore focus on treating?
Immunocore primarily focuses on treating cancer, particularly through its lead product candidate, Imcivree (tebentafusp), which targets metastatic uveal melanoma. In addition to this, the company explores potential applications in other cancers and autoimmune diseases, aiming to enhance the precision of immune-oncology treatments.
When was Immunocore founded?
Immunocore was founded in 2008, originating from research conducted at the University of Oxford. Since its inception, the company has evolved into a leader in the field of T cell-based therapies, fostering innovation and advancing drug candidates into clinical development.
Where is Immunocore headquartered?
Immunocore is headquartered in Abingdon, Oxfordshire, United Kingdom. This location supports the company's rich scientific recruitment and collaborative opportunities with nearby research institutions, biotech firms, and healthcare professionals.
Who are Immunocore's key competitors?
Immunocore faces competition from other biotechnology and pharmaceutical companies that are also focused on immuno-oncology and T cell therapies. Key competitors may include companies like Bristol-Myers Squibb, Merck, and Gilead Sciences, all of which have developed various cancer immunotherapy solutions.
Who are the key executives at Immunocore?
Key executives at Immunocore include the CEO, who is responsible for the company's overall strategy, as well as the Chief Medical Officer, who leads clinical development initiatives. The executive team brings a wealth of experience in biotechnology, pharmaceuticals, and drug development, driving the company's vision and operations.
What is the current price of Immunocore Holdings plc - American Depositary Shares?
The current price of Immunocore Holdings plc - American Depositary Shares is 29.43
When was Immunocore Holdings plc - American Depositary Shares last traded?
The last trade of Immunocore Holdings plc - American Depositary Shares was at 4:00 pm EDT on April 2nd, 2025